Skip to main content
Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. — Investor Relations & Filings

Ticker · DRMA ISIN · US2498451085 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2026-05-29 Capital/Financing Update
Country US United States of America
Listing US DRMA

About Dermata Therapeutics, Inc.

https://www.dermatarx.com/

Dermata Therapeutics is a medical dermatology company that has shifted its strategic focus to developing and commercializing scientifically-backed over-the-counter (OTC) pharmaceutical products. The company leverages its proprietary Spongilla technology, which combines natural elements with FDA-listed OTC ingredients to create differentiated skin care solutions. Its initial product is a once-weekly acne kit, supported by clinical validation from its Phase 3 START-1 trial. Dermata plans to expand its portfolio with product candidates for other common skin conditions, such as psoriasis and seborrheic dermatitis, aiming to provide patients with accessible and effective treatments to manage their skin health.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 93% confidence The document is a Form 424(b)(3) prospectus filed under the Securities Act, detailing a shelf registration for up to $100 million of equity, debt, warrants, subscription rights, and units. It is not an earnings release, annual report, or management discussion—it is a fundraising prospectus. The closest category is Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2026-05-29 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K Current Report, primarily presenting the results of shareholder votes at the 2026 Annual Meeting (Item 5.07 Submission of Matters to a Vote of Security Holders), including detailed vote counts for each proposal. This clearly matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-27 English
S-3/A
Share Issue/Capital Change Classification · 85% confidence The document is an Amendment No. 1 to Form S-3 filed with the SEC and constitutes a shelf registration statement and preliminary prospectus for the offer and sale of up to $100 million of common stock, preferred stock, warrants, debt securities, subscription rights and units. It is not an earnings release, management discussion, or proxy filing, but a full prospectus to raise capital via new securities issuances. Under the classification schema, this falls under “Share Issue/Capital Change” (SHA).
2026-05-22 English
ARS - Dermata Therapeutics, Inc. (0001853816) (Filer)
Annual Report
2026-04-17 English
DEF 14A - Dermata Therapeutics, Inc. (0001853816) (Filer)
Proxy Solicitation & Information Statement
2026-04-17 English
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
Director's Dealing
2026-03-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.